AI Article Synopsis
- The combined therapy of peg-interferon α2a and ribavirin with protease inhibitors (boceprevir or telaprevir) is an effective treatment for hepatitis C.
- A 50-year-old man developed insulin-dependent diabetes shortly after starting this triple therapy.
- As a result of this rare side effect, his treatment had to be halted, complicating his hepatitis C infection management.
Article Abstract
The combined regimen of peg-interferon α2a plus ribavirin along with protease inhibitors (boceprevir or telaprevir) is considered as a very portent and effective therapy for hepatitis C infections. However, this combined therapy has been associated with a side effect that can make the course of the disease more complicated. In this case, a 50-year-old man developed insulin-dependent diabetes soon after initiating triple hepatitis C therapy. The treatment had to be stopped and the course of his hepatitis C infection has been challenged with this rare side effect.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736303 | PMC |
| http://dx.doi.org/10.1136/bcr-2013-200514 | DOI Listing |
Publication Analysis
Top Keywords
hepatitis therapy
8
chronic hepatitis
4
therapy
4
therapy rare
4
rare complication
4
complication revisited
4
revisited combined
4
combined regimen
4
regimen peg-interferon
4
peg-interferon α2a
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!